CTOs on the Move

Ovid Therapeutics

www.ovidrx.com

 
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ovidrx.com
  • 1460 Broadway
    New York, NY USA 10036
  • Phone: 646.661.7661

Executives

Name Title Contact Details
Stephanie Licata
VP, Program Leadership & Portfolio Management Profile

Funding

Ovid Therapeutics raised $75M on 08/11/2015
Ovid Therapeutics raised $25.86M on 01/23/2017
Ovid Therapeutics raised $25M on 02/26/2019
Ovid Therapeutics raised $20M on 02/26/2019

Similar Companies

NextGen

NextGen Healthcare is on a relentless quest to improve the lives of those who practice medicine and those they care for. We provide tailored solutions to fit the precise needs of ambulatory practices, as they strive to reach the quadruple aim while navigating the journey of value-based care. The result? Healthier patients and happier providers.

AlphaVax

AlphaVax is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

Wintersun Chemical

Wintersun Chemical LTD is a Ontario, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

L.A. Care Health Plan

L.A. Care Health Plan is a community-accountable health plan serving Los Angeles County residents through a variety of health coverage programs including L.A. Care Covered™, Medi-Cal, L.A. Care Cal MediConnect Plan and PASC-SEIU Homecare Workers Health Care Plan. L.A. Care is a leader in developing new programs through innovative partnerships designed to provide health coverage to vulnerable populations and to support the safety net. With more than 2 million members, L.A. Care is the nation`s largest publicly operated health plan.